SK Biopharm Signs Supply Contract Worth 48.9 Billion KRW with SK Life Science
[Asia Economy Reporter Minwoo Lee] SK Biopharm announced on the 9th that it has signed a pharmaceutical supply contract worth 48.9 billion KRW with its subsidiary SK Life Science. This amount corresponds to 39.49% of the consolidated sales in 2019.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "I'll Stop by Starbucks Tomorrow": People Power Chungbuk Committee and Geoje Mayoral Candidate Face Criticism for Alleged 5·18 Demeaning Remarks
- Trump Puts Attack on Hold, but "Only for a Certain Period"... Treasury Announces Sweeping Sanctions
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
SK Biopharm explained, "This contract is to supply products to SK Life Science, our local subsidiary in the United States, for the sales of our epilepsy treatment new drug 'Cenobamate' in the US market. It is an internal transaction that is not recorded as sales in the consolidated financial statements."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
